Benjamin Mizukawa

Benjamin E. Mizukawa, MD


  • Research Director, Pediatric Cancer Avatar Program
  • Associate Professor, UC Department of Pediatrics

About

MD: University of Utah, Salt Lake City, UT, 2004.

Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

Fellowship: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

Certification: Pediatrics, 2008; Pediatric Hematology/Oncology, 2011.

Interests

Pediatric leukemia and lymphoma; investigation of the role of small Rho GTPases in leukemogenesis and leukemic stem cell biology and their potential as therapeutic targets in acute myeloid leukemia; development of xenograft models for use in testing novel therapeutics.

Services and Specialties

Cancer and Blood Diseases, Leukemia

Research Areas

Experimental Hematology and Cancer Biology, Oncology, Cancer and Blood Diseases

Additional Languages

French, Japanese

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

P676: UPDATED RESULTS FROM THE TRIAL ITCC‐054/COG‐AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA. Brivio, E; Pennesi, E; Willemse, M; Jiang, Y; van der Velden, V; Beverloo, B; Hudson, C; Kuttschreuter, L; van der Sluis, I; Brethon, B; Locatelli, F; Roth, M; Hijiya, N; Zwaan, M. HemaSphere. 2023; 7:e506783a.

The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Rubinstein, JD; Breese, EH; Krupski, MC; O'Brien, MM; Dandoy, CE; Mizukawa, B; Khoury, R; Norris, RE; Davies, SM; Phillips, CL. Transplantation and Cellular Therapy. 2023; 29:311.e1-311.e7.

Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy. Bender, JD; Rubinstein, JD; Mizukawa, B; Perentesis, JP; Pommert, L. Pediatric Blood and Cancer. 2023; 70:e30214.

IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia. Liu, X; Sato, N; Yabushita, T; Li, J; Jia, Y; Tamura, M; Asada, S; Fujino, T; Fukushima, T; Yonezawa, T; Shibata, T; Miyake, K; Kitamura, T; Goyama, S. EMBO Molecular Medicine. 2023; 15:e15631.

Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis. Nayak, RC; Chang, KH; Singh, AK; Kotliar, M; Desai, M; Wellendorf, AM; Wunderlich, M; Bartram, J; Mizukawa, B; Cuadrado, M; Dexheimer, P; Barski, A; Bustelo, XR; Nassar, NN; Cancelas, JA. Nature Communications. 2022; 13:3056.

Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. Hegde, S; Gasilina, A; Wunderlich, M; Lin, Y; Buchholzer, M; Krumbach, OH F; Akbarzadeh, M; Ahmadian, MR; Seibel, W; Zheng, Y; Perentesis, JP; Mizukawa, BE; Vinnedge, LP; Cancelas, JA; Nassar, NN. Leukemia. 2022; 36:637-647.

PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets. Wunderlich, M; Chen, J; Sexton, C; Manning, N; Byerly, L; O’Brien, E; Perentesis, J; Mulloy, J; Mizukawa, B. 2022; 2022.01.31.478534.

Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. Sabnis, HS; Shulman, DS; Mizukawa, B; Bouvier, N; Zehir, A; Fangusaro, J; Fabrizio, VA; Whitlow, C; Winchester, M; Agresta, L; DuBois, SG; Glade-Bender, J; Castellino, SM; Shukla, N. Journal of Clinical Oncology. 2021; 39:3822-3828.

Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Rubinstein, JD; Shah, R; Breese, EH; Burns, KC; Mangino, JL; Norris, RE; Lee, L; Mizukawa, B; O'Brien, MM; Phillips, CL; Perentesis, JP; Pommert, L; Absalon, MJ. Pediatric Blood and Cancer. 2021; 68:e29126.

Hyperdiploid Precursor B-acute Lymphoblastic Leukemia Presenting as a Cavernous Sinus Mass in a 4-Year-old Male. Sabulski, A; Bartlett, AL; Koch, BL; Vatner, R; Mizukawa, B; Phillips, CL. Journal of Pediatric Hematology/Oncology. 2021; 43:e494-e497.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6
Overall Patient Rating